James F.  Reddoch net worth and biography

James Reddoch Biography and Net Worth

Dr. Reddoch has led the team at Royalty Pharma that focuses on sourcing and analyzing new investment opportunities and partnerships for over 10 years. Prior to joining Royalty Pharma in 2008, Dr. Reddoch was Head of Healthcare Research at FBR Capital Markets. Previously, Dr. Reddoch was a biotechnology analyst at Bank of America and CIBC World Markets. Dr. Reddoch serves on the board of Avillion, a London-based drug development company funded by Royalty Pharma and other investors, and on Memorial Sloan Kettering Cancer Center’s external review board for its Technology Development Fund. Dr. Reddoch has a BA from Furman University, a PhD in biochemistry and molecular genetics from the University of Alabama, and was a postdoctoral fellow at Yale University.

What is James F. Reddoch's net worth?

The estimated net worth of James F. Reddoch is at least $21.55 million as of September 28th, 2022. Dr. Reddoch owns 820,800 shares of Royalty Pharma stock worth more than $21,546,000 as of December 3rd. This net worth estimate does not reflect any other investments that Dr. Reddoch may own. Additionally, Dr. Reddoch receives a salary of $3,400,000.00 as EVP at Royalty Pharma. Learn More about James F. Reddoch's net worth.

How old is James F. Reddoch?

Dr. Reddoch is currently 54 years old. There are 5 older executives and no younger executives at Royalty Pharma. The oldest executive at Royalty Pharma is Mr. George Wingate Lloyd, Executive VP of Investments & Chief Legal Officer, who is 64 years old. Learn More on James F. Reddoch's age.

What is James F. Reddoch's salary?

As the EVP of Royalty Pharma plc, Dr. Reddoch earns $3,400,000.00 per year. There are 3 executives that earn more than Dr. Reddoch. The highest earning executive at Royalty Pharma is Mr. George Wingate Lloyd, Executive VP of Investments & Chief Legal Officer, who commands a salary of $4,560,000.00 per year. Learn More on James F. Reddoch's salary.

How do I contact James F. Reddoch?

The corporate mailing address for Dr. Reddoch and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on James F. Reddoch's contact information.

Has James F. Reddoch been buying or selling shares of Royalty Pharma?

James F. Reddoch has not been actively trading shares of Royalty Pharma during the past quarter. Most recently, James F. Reddoch sold 100,000 shares of the business's stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $41.23, for a transaction totalling $4,123,000.00. Following the completion of the sale, the executive vice president now directly owns 820,800 shares of the company's stock, valued at $33,841,584. Learn More on James F. Reddoch's trading history.

Who are Royalty Pharma's active insiders?

Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (Founder & Chief Executive Officer and Chairman), George Lloyd (EVP), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.

Are insiders buying or selling shares of Royalty Pharma?

In the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 312,631 shares worth more than $8,860,323.39. The most recent insider tranaction occured on January, 4th when Director Rory B Riggs sold 35,702 shares worth more than $983,590.10. Insiders at Royalty Pharma own 18.9% of the company. Learn More about insider trades at Royalty Pharma.

Information on this page was last updated on 1/4/2024.

James F. Reddoch Insider Trading History at Royalty Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/28/2022Sell100,000$41.23$4,123,000.00820,800View SEC Filing Icon  
6/8/2022Sell100,000$41.56$4,156,000.00920,800View SEC Filing Icon  
5/27/2022Sell75,000$41.08$3,081,000.001,020,800View SEC Filing Icon  
5/19/2022Sell75,000$40.44$3,033,000.001,095,800View SEC Filing Icon  
7/14/2021Sell2$42.00$84.00View SEC Filing Icon  
7/8/2021Sell40,655$42.05$1,709,542.753,000View SEC Filing Icon  
7/6/2021Sell30,270$42.40$1,283,448.003,000View SEC Filing Icon  
3/22/2021Sell43,927$46.32$2,034,698.643,000View SEC Filing Icon  
See Full Table

James F. Reddoch Buying and Selling Activity at Royalty Pharma

This chart shows James F Reddoch's buying and selling at Royalty Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Royalty Pharma Company Overview

Royalty Pharma logo
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Read More

Today's Range

Now: $26.25
Low: $26.15
High: $26.33

50 Day Range

MA: $27.15
Low: $25.58
High: $28.38

2 Week Range

Now: $26.25
Low: $25.10
High: $31.66

Volume

574,625 shs

Average Volume

2,628,790 shs

Market Capitalization

$15.47 billion

P/E Ratio

13.60

Dividend Yield

3.15%

Beta

0.46